Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
- DOI
- 10.1016/s2215-0366(21)00386-2
- Published
- 2022 Jan
- Container
- The lancet. Psychiatry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2215-0366-21-00386-2,
title = {Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.},
author = {Bugarski-Kirola D and Arango C and Fava M and Nasrallah H and Liu IY and Abbs B and Stankovic S},
year = {2022},
journal = {The lancet. Psychiatry},
doi = {10.1016/s2215-0366(21)00386-2},
url = {https://doi.org/10.1016/s2215-0366(21)00386-2}
}RIS
TY - JOUR TI - Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. AU - Bugarski-Kirola D AU - Arango C AU - Fava M AU - Nasrallah H AU - Liu IY AU - Abbs B AU - Stankovic S PY - 2022 JO - The lancet. Psychiatry DO - 10.1016/s2215-0366(21)00386-2 UR - https://doi.org/10.1016/s2215-0366(21)00386-2 ER -
APA
D, B., C, A., M, F., H, N., IY, L., B, A., & S, S. (2022). Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.. The lancet. Psychiatry. https://doi.org/10.1016/s2215-0366(21)00386-2
Source records
- pubmed · retrieved 2026-09-26T05:24:07.953Z